Development of treatment for severe heart failure using autologous myoblast sheet

Development of treatment for severe heart failure using autologous myoblast sheet - Autologous myoblast sheets transplantation therapy for cardiomyopathy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012906

Enrollment

Registered

2014-01-21

Start date

2014-01-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dilated cardiomyopathy, Ischemic cardiomyopathy

Interventions

Culture of autologous skeletal myoblasts and engineering myoblast sheets. Transplantation of myoblast sheets to heart Patients with maximal medical and surgical treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Dilated cardiomyopathy and ischemic cardiomyopathy 2) NYHA Class II,III, IV 3) Ejection fraction<35%

Exclusion criteria

Exclusion criteria: 1) Severe skeletal muscle disease 2) Severe infection 3) Alcoholic or drug addiction in recent six months 4) Malignancy 5) Virus infection (HIV, HBV, HCV,HTLV) 6) Pregnancy 7) Others

Design outcomes

Primary

Measure	Time frame
Improvement of LV ejection fraction	—

Secondary

Measure	Time frame
1) Feasibility of myoblast sheet implantation 2) Improvement of regional function 3) LV reverse remodeling 4) Improvement of symptoms and grade of heart failure 5) Adverse event	—

Countries

Japan

Contacts

Public ContactShigeru Miyagawa

Osaka University Graduate School of Medicine Cardiovascular surgery

miyagawa@surg1.med.osaka-u.ac.jp06-6879-3154

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026